Nicox completes the acquisitions of Doliage and of the Carragelose(r) anti-viral eye drop program

SOPHIA ANTIPOLIS, France, Sept. 26, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Doliage, a privately-held French ophthalmic company. The acquisition is part of Nicox's strategy to develop an ophthalmic commercial infrastructure in the five major European markets and provides Nicox with an established and profitable ophthalmic business in France.

For more information, please refer to:

• Press release dated September 16, 2014: Nicox continues European ophthalmic expansion with acquisition of Doliage in France
• Press release dated September 25, 2014 (in French): Emission par Nicox de 2 235 134 actions en rémunération de l'apport de la totalité du capital de la société Laboratoires Doliage

Nicox also announced the completion of the acquisition of the Carragelose^® anti-viral eye drop program from Marinomed Biotechnologie GmbH. This acquisition provides Nicox with an innovative anti-viral ophthalmic product which could be launched in Europe within two years, pending CE marking, for the management of viral conjunctivitis. As per the terms of the agreement, Nicox has acquired the rights to the Carragelose^® anti-viral eye drop program through the acquisition of AVEye Biotechnologie GmbH, a wholly-owned affiliate of Marinomed which owns the entirety of the eye drop program.

For more information, please refer to:

• Press release dated September 16, 2014: Nicox acquires Carragelose^® anti-viral eye drop program
• Press release dated September 25, 2014 (in French): Emission par Nicox de 1 240 636 actions en rémunération de l'apport de la totalité du capital de la société AVEye Biotechnologie GmbH

...................................

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is VESNEO (latanoprostene bunod), a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com.

..................................

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4^th chapter of the "Document de référence, rapport financier annuel et rapport de gestion 2013" filed with the French Autorité des Marchés Financiers (AMF) on April 2^nd, 2014 and in the "Rapport semestriel financier et d'activité au 30 juin 2014" available on Nicox's website (www.nicox.com).

...................................

Press release http://hugin.info/143509/R/1858436/650891.pdf

HUG#1858436